Fox Chase Cancer Center News

PHILADELPHIA (January 29, 2025) — Emma Guilbaud, PhD, a postdoctoral associate at Fox Chase Cancer Center, has been selected as a Forbeck Scholar by the William Guy Forbeck Research Foundation. This prestigious appointment recognizes early career cancer researchers for their achievements, research, and dedication to the field.

PHILADELPHIA (January 24, 2025) — The number of patients receiving immune checkpoint inhibitors and PD-L1 testing for treatment of gastroesophageal cancer (GEC) increased following Food and Drug Administration (FDA) approval, according to a new study presented by researchers at Fox Chase Cancer Center.

PHILADELPHIA (January 21, 2025) — Fox Chase Cancer Center is pleased to announce the hiring of Hanzhi Luo, PhD, as an Assistant Professor in the Nuclear Dynamics and Cancer Research Program and a member of the Cancer Epigenetics Institute (CEI).

PHILADELPHIA (January 21, 2025) — Fox Chase Cancer Center is pleased to announce the hiring of Weiran Feng, PhD, as an Assistant Professor in the Nuclear Dynamics and Cancer Research Program and a member of the Cancer Epigenetics Institute (CEI).

PHILADELPHIA (January 21, 2025) — Yash Chhabra, PhD, Assistant Professor in the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center, was recently honored with the American Association for Cancer Research’s (AACR) NextGen Stars Award.

PHILADELPHIA (January 13, 2025) — Roland Dunbrack, PhD, professor in the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center, has been appointed co-leader of the program alongside its current leader, Edna (Eti) Cukierman, PhD.

PHILADELPHIA (January 9, 2025) — Fox Chase Cancer Center is pleased to announce the hiring of Qing Chen, MD, PhD, as an Associate Professor in the Cancer Signaling and Microenvironment Research Program.

PHILADELPHIA (December 7, 2024) — Fox Chase Cancer Center researchers have identified a pretreatment protocol that reduces side effects for the drug motixafortide, which is sold under the brand name Aphexda. The findings, which were presented today at the annual meeting of the American Society of Hematology, has significantly improved the comfort and quality of life for multiple myeloma patients undergoing autologous stem cell transplant.